Latest in: Homepage
Homepage · News · Press

Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101 and Appoints Keith Orford, MD, PhD, as Chief Medical Officer 

Tagworks initiates Phase 1 trial for TGW101, a first-in-class Click-to-Release ADC targeting TAG-72, and appoints Dr. Keith Orford as Chief Medical Officer.
April 22, 2025
Events · Homepage

Tagworks Pharmaceuticals Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025

Tagworks to present preclinical data demonstrating potential of its Click-to-Release platform to enable safe, tolerable, and potent delivery of therapeutic candidates for solid tumors
March 25, 2025
Homepage · News

Tagworks Pharmaceuticals Appoints Ken Mills as Chief Executive Officer

Biotech industry veteran to lead Tagworks as the company prepares to bring its novel platform and lead antibody-drug conjugate (ADC) program for solid tumors into the clinic in 2025
October 1, 2024

Curious about what we do? Get in touch!

CONTACT US
Logo-2

About    Our Technology   Pipeline    Join us    News    Contact

Contact
T +31 85 800 8550
info@tagworkspharma.com

Address
Tagworks Pharmaceuticals BV
Toernooiveld 1
6525 ED  Nijmegen
The Netherlands

Stay updated

© Tagworks Pharmaceuticals, 2025 | Terms of use | Design by Ape to Zebra